159 related articles for article (PubMed ID: 29242296)
1. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
[No Abstract] [Full Text] [Related]
2. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
[TBL] [Abstract][Full Text] [Related]
3. Rituximab maintenance therapy in central nervous system lymphoma?
Murawski N; Pfreundschuh M
Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314
[No Abstract] [Full Text] [Related]
4. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
Ben-Barouch S; Kuruvilla J
Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
[No Abstract] [Full Text] [Related]
5. Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
Cheah CY; Seymour JF
Leuk Lymphoma; 2014 Mar; 55(3):471-3. PubMed ID: 23906017
[No Abstract] [Full Text] [Related]
6. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Maerevoet M; Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Van Den Neste E; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M
J Hematol Oncol; 2021 Jul; 14(1):111. PubMed ID: 34271963
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system involvement of primary cutaneous diffuse large B cell lymphoma-leg type diagnosed according to the WHO 2008 classification.
Aoki K; Arima H; Tabata S; Matsushita A; Ishikawa T; Takahashi T
Ann Hematol; 2012 Dec; 91(12):1975-6. PubMed ID: 22592652
[No Abstract] [Full Text] [Related]
8. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study.
Kim SJ; Hong JS; Chang MH; Kim JA; Kwak JY; Kim JS; Yoon DH; Lee WS; Do YR; Kang HJ; Eom HS; Park Y; Won JH; Mun YC; Kim HJ; Kwon JH; Kong JH; Oh SY; Lee S; Bae SH; Yang DH; Jun HJ; Kim YS; Yun HJ; Lee SI; Kim MK; Park EK; Kim WS; Suh C
Oncotarget; 2016 Nov; 7(44):72033-72043. PubMed ID: 27713132
[TBL] [Abstract][Full Text] [Related]
9. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
Richard S; Richter J; Jagannath S
Future Oncol; 2020 Jul; 16(19):1331-1350. PubMed ID: 32511022
[TBL] [Abstract][Full Text] [Related]
10. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
Kansara R; Villa D; Gerrie AS; Klasa R; Shenkier T; Scott DW; Slack GW; Gascoyne RD; Connors JM; Sehn LH; Savage KJ
Br J Haematol; 2017 Nov; 179(3):508-510. PubMed ID: 27443424
[No Abstract] [Full Text] [Related]
11. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
12. Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma.
Xu H; Li H; Wada R; Bader JC; Tang S; Shah J; Shacham S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):69-79. PubMed ID: 33770229
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
[No Abstract] [Full Text] [Related]
14. Primary renal diffuse large B-cell lymphoma with central nervous system involvement: a rare case report and literature review.
Wang Y; Guo S
Int J Clin Exp Pathol; 2015; 8(6):7045-9. PubMed ID: 26261597
[TBL] [Abstract][Full Text] [Related]
15. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
Sylvain C
Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
Cox MC; Mannino G; Lionetto L; Naso V; Simmaco M; Spiriti MA
Am J Hematol; 2011 Nov; 86(11):957. PubMed ID: 21990093
[No Abstract] [Full Text] [Related]
17. Intraocular (vitreoretinal) lymphoma with renal, pelvic, and central nervous system lesions.
Bhatt N; Fox A; Chan CC; Roschewski M; Sen HN
Can J Ophthalmol; 2014 Aug; 49(4):e104-6. PubMed ID: 25103663
[No Abstract] [Full Text] [Related]
18. Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.
Zhou Y; Xu X
Hematology; 2022 Dec; 27(1):105-112. PubMed ID: 35068379
[TBL] [Abstract][Full Text] [Related]
19. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Zhang J; Chen B; Xu X
Leuk Lymphoma; 2014 Mar; 55(3):509-14. PubMed ID: 23741977
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.
Cheah CY; Joske D; Cull G; Gilbertson M; Opat SS; Tam CS; Wirth A; Seymour JF
Br J Haematol; 2017 Sep; 178(6):991-994. PubMed ID: 27470657
[No Abstract] [Full Text] [Related]
[Next] [New Search]